Bilirubin Assay Kits Market: Overview
Red blood cells are broken down in the
reticuloendothelial system, primarily the spleen. The dead cells inside
the spleen are converted to bilirubin upon removal of iron. This process
accounts for about 80% of the bilirubin formed every day inside a human
body. The bilirubin is transferred to liver in the form of indirect or
unconjugated bilirubin. Conjugated bilirubin is excreted via the biliary
system into the intestine, where it is metabolized by bacteria known
collectively as stercobilinogen. The body produces bilirubin in the form
of unconjugated and conjugated fractions. The bilirubin is elevated in
hepatitis, cirrhosis, hemolytic disorders, several inherited enzyme
deficiencies, and conditions causing hepatic obstruction. Rise in
incidence of hepatitis in neonates, adults, and liver-related diseases
increases the usage of bilirubin assay kits, which in turn drives demand
of tests using bilirubin assay kits among the population. Moreover, new
developments in analytical method and diagnostic technique approaches
are paving the way for early diagnosis and treatment of liver diseases.
High prevalence of diseases such as
hepatitis, cirrhosis, and other liver related diseases, increase in the
geriatric population, and rise in research & development initiatives
are projected to drive the global bilirubin assay kits market.
Additionally, advent in constituent of exogenous markers, rise in
government funding, increase in the number of initiatives for clinical
laboratories, development of innovative intravesical therapies, and
aggressive marketing by pharma companies propel the global market.
Favorable reimbursements, novel treatments, robust pipeline, and patent
cliff of certain assays are anticipated to boost the growth of the
global bilirubin assay kits market during the forecast period. However,
high cost of treatment using bilirubin assay kits and time consuming
process of using assays are expected to be major restraints of the
global market during the forecast period.
The global bilirubin assay kits market
can be segmented based on age group, disease type, end-user, and region.
In terms of age group, the market can be bifurcated into adults and
neonates & infants. Based on disease type, the global bilirubin
assay kits market can be classified into hemolytic jaundice, obstructive
jaundice, hepatic jaundice, cirrhosis, and others. The hemolysis
jaundice segment is projected to grow at a rapid pace owing to increase
in number of patients with unconjugated bilirubin level. Rise in the
number of neonates is a major factor anticipated to fuel the growth of
the hemolytic jaundice segment in the near future. In terms of end-user,
the market can be divided into hospital laboratories, clinical
laboratories, research & labs, and others.
Bilirubin Assay Kits Market: Regional Analysis
Based on region, the global bilirubin
assay kits market can be segmented into North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. North America
dominated the global market in 2018 due to large geriatric population
suffering from liver diseases, rise in the number of devices receiving
regulatory approvals, FDA approval for assays & kits, and increase
in demand for new and advanced kits for clinical tests. Increase in the
incidence of liver diseases, early phase diagnosis of cirrhosis, and
treatment of other liver diseases drive the pharmaceutical industries
market. This in turn is expected to augment the bilirubin assay kits
market in North America. Europe was the second largest market for
bilirubin assay kits in 2018 due to favorable government policies
regarding the development of health care infrastructure and
laboratories. Expansion of research and development units and pathology
labs in countries in Europe is also a major factor likely to drive the
bilirubin assay kits market in the region. The market in Asia Pacific is
projected to expand at a high CAGR during the forecast period due to
increase in geriatric population with chronic diseases. Rise in
awareness among patients about liver diseases, jaundice among premature
babies, and increase in per capita health care expenditure are factors
anticipated to fuel the growth of the bilirubin assay kits market in
Asia Pacific. Additionally, economic growth which supports health care
infrastructure in India and China and expansion of pharmaceutical
companies and biotech labs are expected to boost the growth of the
market in Asia Pacific from 2019 to 2027.
Major players operating in the global
bilirubin assay kits market are Randox Laboratories Ltd., Roche
Diagnostics, Danaher Corporation, Siemens Diagnostics (Siemens AG),
Johnson & Johnson, Merck KGaA, POINTE Scientific, Inc., and Reckon
Diagnostics P. Ltd., among others.
No comments:
Post a Comment